aprepitant for the prevention of chemotherapy-
induced nausea and vomiting in patients with
breast cancer after moderately emetogenic
chemotherapy. J Clin Oncol 2005;23(12):
2822–30.
26 Gore L et al. Aprepitant in adolescent patients
for prevention of chemotherapy-induced nausea
and vomiting: A randomized, double-blind,
placebo-controlled study of efficacy and
tolerability. Pediatr Blood Cancer 2009;52:242–7.
27 Bošnjak SM, Gralla RJ, Schwartzberg L.
Prevention of chemotherapy-induced nausea:
the role of neurokinin-1 receptor antagonists.
Support Care Cancer 2017;Jan 20 doi: 10.1007/
s00520-017-3585-z.
28 Emend aprepitant capsules. Summary of
Product Characteristics. www.medicines.org.uk/
emc/ (accessed July 2018).
29 Patel P et al. Aprepitant and fosaprepitant
drug interactions: a systematic review. Br J Clin
Pharmacol 2017;83(10):2148–62.
30 Ivemend. Summary of Product
Characteristics. https://www.medicines.org.uk/
emc/product/5947/smpc (accessed July 2019).
31 Kataria PS, Kendre PP, Patel AA. Ifosfamide-
induced encephalopathy precipitated by
aprepitant: A rarely manifested side effect of
drug interaction. J Pharmacol Pharmacother
2017;8(1):38–40.
32 Kang HJ et al. Aprepitant for the prevention
of chemotherapy-induced nausea and vomiting
in paediatric subjects: An analysis by age group.
Pediatr Blood Cancer 2018:e27273.
33 Emend powder for suspension. Summary of
Product Characteristics. www.medicines.org.uk/
emc/product/7385/smpc (accessed July 2019).
34 Chau E et al. Updated report on incidence
of infusion-site reactions associated with
peripheral intravenous administration
of fosaprepitant. J Oncol Pharm Pract
2019;25(5):1053–7.
35 Baxley A, Lee Z, Medina P. Systemic
hypersensitivity to fosaprepitant - A report
of two cases. J Oncol Pharm Pract. 2018
Jan;24(1):76–8.
36 Walton GD. Safety profile of HTX-019
administered as an intravenous push in cancer
patients: A retrospective review. Adv Ther
2019;36(3):662–9.
37 Karthaus M et al. Neurokinin-1 receptor
antagonists: review of their role for the
prevention of chemotherapy-induced nausea
and vomiting in adults. Expert Rev Clin
Pharmacol 2019;12(7):661–80.
38 Leal AD et al. Fosaprepitant-induced
phlebitis: a focus on patients receiving
doxorubicin/cyclophosphamide therapy. Support
Care Cancer 2014;22:1313–7.
39 Hegerova LT et al. An analysis of
fosaprepitant-induced venous toxicity in patient
receiveing highly emetogenic chemotherapy.
Support Care Cancer 2015;23:55–9.
40 https://www.cinvanti.com/pdfs/CINVANTI_
PI_02.2019.pdf.
41 Ottoboni T et al. Bioequivalence of HTX-019
(aprepitant IV) and fosaprepitant in healthy
subjects: a Phase I, open-label, randomized,
two-way crossover evaluation. Drug Des Devel
Ther 2018;12:429–35.
42 Jordan K et al. Efficacy benefit of an NK1
receptor antagonist (NK1RA) in patients
receiving carboplatin: supportive evidence
with NEPA (a fixed combination of the NK1
RA, netupitant, and palonosetron) and
aprepitant regimens. Support Care Cancer
2016;24(11):4617–25.
43 Lorusso V. Management of management of
chemotherapy induced nausea and vomiting
by risk profile: role of netupitant/palonosetron.
Ther Clin Risk Manag 2016;12:917–25.
44 Natale JJ et al. Drug–drug interaction
profile of components of fixed combination of
netupitant and palonosetron: Review of clinical
data. J Oncol Pharm Pract 2016;22(3):485–95.
45 Hesketh PJ et al. A review of NEPA, a
novel fixed antiemetic combination with the
potential for enhancing guideline adherence
and improving control of chemotherapy-
induced nausea and vomiting. Biomed Res Int
2015;2015:651879.
46 Akynzeo. Summary of Product
Characteristics. www.medicines.org.uk/emc/
(accessed July 2019).
47 Schwartzberg L et al. Safety of intravenous
(IV) NEPA and oral NEPA for prevention of
CINV in patients (pts) with breast cancer (BC)
receiving anthracycline/cyclophosphamide (AC)
chemotherapy (CT). J Clin Oncol 2019;37:11594.
https://ascopubs.org/doi/abs/10.1200/
JCO.2019.37.15_suppl.11594.
48 Navari R. Rolapitant hydrochloride:
prophylactic treatment for chemotherapy-
induced nausea and vomiting. Drugs Today
(Barc) 2016;52(8):431–8.
49 Navari RM et al. Rolapitant for the prevention
of nausea in patients receiving highly or
moderately emetogenic chemotherapy. Cancer
Med 2018;May 23.
50 Varubi. Summary of Product Characteristics.
http://varubirx.com/ (accessed June 2019).
51 Chasen M et al. Rolapitant improves
quality of life of patients receiving highly or
hospitalpharmacyeurope.com | 2019 | 67